Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity

May 2, 2024

https://www.globenewswire.com/news-release/2024/05/02/2874205/0/en/Elevai-Biosciences-Highlights-Preclinical-Data-Showing-Potential-of-In-Licensed-Asset-EL-22-for-The-Treatment-of-Obesity.html

NEWPORT BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) — Elevai Labs, Inc. (NASDAQ:ELAB) (“Elevai” or the “Company”), today highlights results from our licensor’s 2022 preclinical studies evaluating the treatment effect of its recently in-licensed asset, EL-22. EL-22 will primarily be commercialized by Elevai Biosciences, Inc., a biopharmaceutical division of the Company focusing on the development and acquisition of cutting-edge aesthetic medicines. Based on our licensor’s 2022 preclinical data, Elevai believes that EL-22 has the potential to treat obesity in combination with GLP-1 receptor agonists by preserving muscle mass while decreasing fat mass.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.